← Oncology Approval Tracker

FDA DECISION ·

Libtayo

cemiplimab-rwlc · Regeneron

Traditional approvalTraditional conversionBasal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For metastatic basal cell carcinoma after a hedgehog pathway inhibitor or when such an inhibitor is unsuitable.

LAMPGEN ANALYSIS

Why it matters

FDA converted the accelerated metastatic basal cell carcinoma use after confirmatory evidence.

What research teams should watch

Document prior hedgehog inhibitor treatment or the reason it is unsuitable and keep this entry separate from locally advanced disease.

PRIMARY RECORDS

Sources